Oral Calcium Folinate Dosing for Methotrexate-Induced Mucositis
For established methotrexate-induced mucositis, administer calcium folinate (leucovorin) 10 mg/m² orally every 6 hours immediately upon recognition, continuing until mucositis resolves. 1
Dosing Algorithm
For Acute Mucositis Treatment
When methotrexate-induced mucositis is present:
- Initial dose: 10 mg/m² orally every 6 hours 1
- Timing: Begin immediately when mucositis is identified
- Duration: Continue until mucosal ulceration has healed 2
- Route consideration: If gastrointestinal toxicity, nausea, or vomiting are present, switch to parenteral administration 1
For Overdose Situations (Higher Risk)
If methotrexate overdose is suspected with mucositis:
- Initial dose: Up to 100 mg/m² IV if methotrexate level unknown, then switch to oral/IV dosing at the same dose every 6 hours 2
- Critical timing: Most effective when initiated within hours of last methotrexate dose; doubtful efficacy if started >24 hours later 2
- Monitoring endpoint: Continue until methotrexate levels <0.05 µmol/L AND mucosal ulceration has healed 2
Important Clinical Considerations
Dose Limitations
Doses greater than 25 mg should be given parenterally, not orally, due to saturable absorption 3. This is critical—oral bioavailability plateaus above 25 mg, making higher oral doses ineffective.
Supportive Measures
Concurrent management must include:
- Aggressive hydration (3 L/day) 2
- Urinary alkalinization with sodium bicarbonate to maintain urine pH ≥7.0 2
- Monitor for sepsis given high mortality risk with methotrexate overdose 2
Prevention Context
The evidence distinguishes between treatment (your question) and prevention. For prevention of mucositis in patients on chronic low-dose methotrexate, folic acid 1-5 mg daily (except on methotrexate day) is recommended 1. However, once mucositis develops, leucovorin (folinic acid) is required as it bypasses the metabolic block created by methotrexate 1.
Evidence Quality Note
The 10 mg/m² every 6 hours dosing comes from established dermatology guidelines 1 addressing hematologic toxicity and mucositis from low-dose methotrexate. The British Association of Dermatologists guideline 2 provides the most comprehensive overdose protocol, specifying continuation until both laboratory and clinical (mucosal healing) endpoints are met. The FDA label 3 confirms the oral absorption limitation, which is crucial for dose selection.
Recent research 4 comparing 15 mg vs 25 mg leucovorin every 6 hours in severe low-dose methotrexate toxicity found no survival difference, though this studied IV administration. The 10 mg/m² dose (approximately 15-20 mg for average adults) represents the established standard that balances efficacy with the oral absorption ceiling.